The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients

This article was published in the following Dove Press journal:
Cancer Management and Research

Xian Wu^{1,*}
Chaoran Ye^{1,*}
Xingmeng Wang²
Ruyu Cai¹
Junzhe Yang¹
Xiafei Yu¹
Yi Zhou¹
Li Shen¹
Yanhui Zhu¹
Xiaoan Liu¹

¹Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China; ²Department of General Surgery, The First People's Hospital of Yancheng City, Yancheng, 224006, People's Republic of China

*These authors contributed equally to this work

Purpose: To retrospectively analyze the efficacy and toxicity of epirubicin plus cyclophosphamide followed by docetaxel (EC-D) and epirubicin plus cyclophosphamide followed by paclitaxel (EC-P) efficacy as neoadjuvant chemotherapy regimens by pathological complete response (pCR) in this study.

Methods: In total, 455 patients diagnosed with breast cancer who received NAC from January 2014 to January 2019 were enrolled. Of which, 109 patients received EC-D (E: 90, C: 600, D: 80, all in mg/m²) and 346 were treated with EC-P (E: 90, C: 600, D: 175, all in mg/m²). Efficacy of NAC regimens was evaluated by pCR, and the toxicity was studied. Chi-squared test was used at $p=0.05$.

Results: In EC-D, 11 patients received ypT_{0/is}N₀, and 6 of them got ypT₀N₀. Analogously, 67 patients receiving received EC-P obtained ypT_{0/is}N₀, and 43 people of them acquired ypT₀N₀. The rate of pCR in EC-P was higher than EC-D. Patients with ER (-), PR (-), Her-2 (+) and high Ki-67 index were easier to were more likely to acquire pCR. Two pCRs were described, the pCR of NAC differed according to the definition. In terms of side effects, there was no significant difference in platelet and urea, but the decrease of hemoglobin and creatinine levels after EC-P treatment was more significant than that after EC-D treatment.

Conclusion: The efficacy of EC-P is better than EC-D if pCR is to be determined as a surrogate end-point for prognosis. The patients with anemia or renal insufficiency who need to receive NAC should choose EC-D.

Keywords: neoadjuvant chemotherapy, pathological complete response, EC-D, EC-P, toxicity of anticancer drugs

Introduction

Breast cancer is the most common tumor in women and the second cause of cancer-related mortality globally.¹ So far, a growing number of therapies have been investigated to treat breast carcinomas. Among them, neoadjuvant chemotherapy (NAC) is very important, as it can observe chemosensitivity and reduce micro-metastasis for locally advanced breast malignancy.² Most significantly, it can reduce the size of the tumor and provide patients with more surgical options.

NAC has many regimes. As reported, adding taxanes to an anthracycline-based regime further reduces recurrence and mortality,³ and thus, plays an important role

Correspondence: Yanhui Zhu; Xiaoan Liu
Tel +86-25-68308152
Email yanhui1002@hotmail.com;
liuxiaoan@126.com

in NAC. However, the optimal dose and interval period of this regime remain to be discussed.

The principal outcome endpoint of NAC is the pathological complete response (pCR) rate, which has two main explanations.⁴ One explanation (ypT_0/isN_0) is that surgical specimens have no invasive tumour cells, but ductal carcinoma in situ (DCIS) can be allowed in breast is permissible. The other one (ypT_0N_0) is that no tumor cell can appear in the breast and lymph nodes, including DCIS. In this retrospective study, these two explanations of pCR were discussed separately.

Firstly, the efficacy and adverse effects were compared between two groups: (1) epirubicin and cyclophosphamide followed by docetaxel every 3 weeks (EC-D) and (2) epirubicin and cyclophosphamide followed by paclitaxel every 2 weeks (EC-P) in NAC. Then, the correlations among different curative effects and factors (eg age, menstrual status, molecular type) were investigated in order to dig out the therapy and individualized treatment of breast cancer.

Methods

Patients

This retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, and the Helsinki Declaration. In addition, written and informed consents were received from the patients. Totally 455 patients diagnosed with breast cancer who received NAC at the tested Hospital from January 2014 to January 2019 were recruited.

Inclusion criteria were as follows:

- (1) Gender: female
- (2) Age: ≥ 18 years old
- (3) Diagnosis of breast cancer by pathology
- (4) Preoperative chemotherapy
- (5) Eastern Cooperative Oncology Group (ECOG)

grade: 0–1

Exclusion criteria were as follows:

- (1) Gender: male
- (2) Age: < 18 years old
- (3) ECOG grade: 2 and above
- (4) Surgery during chemotherapy interval
- (5) Incomplete postoperative pathological data
- (6) Patients with kidney disease and blood disease

Evaluation Parameters

Histological diagnosis, estrogen receptor (ER) status, progesterone receptor (PR) status, Her-2 status and Ki-67

index were detected via standard immunohistochemistry (IHC), Her-2 status would be confirmed by fluorescence in situ hybridization If 2+ IHC staining was present. The molecular typing was divided into four types: luminal A-like, luminal B-like, Her-2 overexpression, and triple-negative breast cancer (TNBC). The definitions of pCR were the same as above. Furthermore, we compared the effects of different NAC regimens on hemoglobin, platelets and renal function, and provided these results using Sysmexs-800i hematology analyzer (Sysmex Corporation, Kobe, Japan).

Treatment

The doses of NAC were decided based on the Chinese Society of Clinical Oncology (CSCO) guidelines for breast cancer: (1) epirubicin plus cyclophosphamide (E:90 mg/m², C:600 mg/m²) every 3 weeks for four cycles followed by docetaxel (D:80 mg/m²,) every 3 weeks for four cycles; (2) epirubicin plus cyclophosphamide (E:90 mg/m², C:600 mg/m²) every 2 weeks for four cycles followed by paclitaxel (D:175 mg/m²) every 2 weeks for four cycles. Patients with Her-2 (+) disease were concomitantly treated with trastuzumab in the four cycles and then with trastuzumab for 1 year totally. All people received systematic granulocyte colony-stimulating factor (G-CSF) 48 hours after chemotherapy.

Statistical Analysis

Data were analyzed on SPSS 22.0. Mean and standard deviation (SD) were evaluated using an independent sample *t*-test. In the univariate analysis, the predictive factors influencing pCR in NAC were acquired via Chi-square test. Independent predictors of pCR were identified by multivariate binary logistic regression. The levels of hemoglobin, platelets, serum creatinine and blood urea were compared via two-sample Wilcoxon rank-sum (Mann–Whitney) test. $P < 0.05$ was considered significant.

Results

Patients

A total of 455 patients (EC-D: 109, EC-P: 346) were included from January 2014 to January 2019. Table 1 summarizes patient characteristics. In the EC-D group, 11 patients were ypT_0/isN_0 , and of them 6 got ypT_0N_0 . Analogously, 67 patients in the EC-P group were ypT_0/isN_0 , and of them 43 acquired ypT_0N_0 .

Table I Patient and Tumor Features

	EC-D (Total:109)				EC-P (Total:346)			
	ypT _{0/is} N ₀	No ypT _{0/is} N ₀	ypT ₀ N ₀	No ypT ₀ N ₀	ypT _{0/is} N ₀	No ypT _{0/is} N ₀	ypT ₀ N ₀	No ypT ₀ N ₀
Age of diagnosis								
≤45	1(0.92%)	27(24.77%)	1(0.92%)	27(24.77%)	22(6.36%)	99(28.61%)	12(3.47%)	109(31.50%)
45–60	7(6.42%)	53(48.62%)	4(3.67%)	56(51.37%)	34(9.83%)	142(41.04%)	20(5.78%)	156(45.09%)
>60	3(2.75%)	18(16.52)	1(0.92%)	20(18.35%)	11(3.18%)	38(10.98%)	11(3.18%)	38(10.98%)
Menstrual status								
Premenopausal	4(3.66%)	47(43.12%)	2(1.84%)	49(44.95%)	38(10.98%)	150(43.35%)	18(5.20%)	170(49.13%)
Peri-menopause	1(0.92%)	3(2.75%)	1(0.92%)	3(2.75%)	0(0)	8(2.31%)	0(0)	8(2.31%)
Postmenopausal	6(5.51%)	47(43.12%)	3(2.75%)	50(45.87%)	29(8.38%)	115(33.24%)	25(7.23%)	119(34.39%)
Unknown	0(0)	1(0.92%)	0(0)	1(0.92%)	0(0)	6(1.74%)	0(0)	6(1.74%)
Molecular type								
Luminal A	0(0)	1(0.92%)	0(0)	1(0.92%)	0(0)	13(3.76%)	0(0)	13(3.76%)
Luminal B	3(2.75%)	66(60.55%)	2(1.83%)	67(61.47%)	23(6.65%)	156(45.09%)	9(2.60%)	170(49.13%)
Her2 overexpression	6(5.50%)	22(20.18%)	3(2.75%)	25(22.94%)	25(7.22%)	47(13.58%)	17(4.91%)	55(15.90%)
TNBC	2(1.84%)	7(6.42%)	1(0.92%)	8(7.34%)	19(5.49%)	55(15.90%)	17(4.91%)	57(16.47%)
Unknown	0(0)	2(1.84%)	0(0)	2(1.83%)	0(0)	8(2.31%)	0(0)	8(2.32%)
ER status								
Positive	3(2.75%)	68(62.39%)	2(1.84%)	69(63.30%)	23(6.65%)	167(48.26%)	9(2.60%)	181(52.31%)
Negative	8(7.34%)	28(25.69%)	4(3.66%)	32(29.36%)	44(12.72%)	105(30.35%)	34(9.83%)	115(33.24%)
Unknown	0(0)	2(1.83%)	0(0)	2(1.84%)	0(0)	7(2.02%)	0(0)	7(2.02%)
PR status								
Positive	2(1.84%)	45(41.28%)	2(1.84%)	45(41.28%)	13(3.76%)	140(40.46%)	4(1.16%)	149(43.06%)
Negative	9(8.26%)	50(45.87%)	4(3.67%)	55(50.46%)	54(15.61%)	131(37.86%)	39(11.27%)	146(42.20%)
Unknown	0(0)	3(2.75%)	0(0)	3(2.75%)	0(0)	8(2.31%)	0(0)	8(2.31%)
Her-2 status								
Positive	9(8.25%)	38(34.86%)	5(4.58%)	42(38.53%)	39(11.27%)	92(26.59%)	21(6.07%)	110(31.79%)
Negative	2(1.84%)	58(53.21%)	1(0.92%)	59(54.13%)	28(8.09%)	178(51.45%)	22(6.36%)	184(53.18%)
Unknown	0(0)	2(1.84%)	0(0)	2(1.84%)	0(0)	9(2.60%)	0(0)	9(2.60%)
Ki-67 index								
≤ 14%	0(0)	3(2.75%)	0(0)	3(2.75%)	1(0.29%)	28(8.09%)	0(0)	29(8.38%)
> 14%	11(10.09%)	93(85.32%)	6(5.50%)	98(89.91%)	66(19.08%)	243(70.23%)	43(12.43%)	266(76.88%)
Unknown	0(0)	2(1.84%)	0(0)	2(1.84%)	0(0)	8(2.31%)	0(0)	8(2.31%)

The baseline characteristics were well balanced between groups. The median age was 50 years (range: 24 to 75 years old).

Exposure to Treatment

According to several key prognostic factors (eg age of diagnosis, menstrual status, molecular type, ER status, PR status, Her-2 status, Ki-67 index), we compared the efficacy between EC-D and EC-P. Details can be found in the following tables.

The univariable analysis for ypT_{0/is}N₀ in NAC showed the significant prognostic factors were chemotherapy

scheme, molecular type, ER status, PR status, Her-2 status, and Ki-67 index ($P < 0.05$; Table 2). When these factors were incorporated into the multivariate regression analysis, molecular type was retained as the independent predictor of pCR of ypT_{0/is}N₀ (odds ratio (OR): 9.495, 95% CI: 0.492–36.176) along with ER status (OR: 0.085, 95% CI: 0.013–0.561) and Her-2 status (OR: 0.055, 95% CI: 0.017–0.183) (all $P < 0.05$). Multivariate regression analysis proved chemotherapy scheme (OR: 1.797, 95% CI: 0.882–3.660), PR status (OR: 1.395, 95% CI: 0.46–4.23) and ki-67 index (OR: 0.444, 95% CI: 0.089–2.219) had no predictive value for ypT_{0/is}N₀ (all $P > 0.05$).

Table 2 The Analysis of ypT_{0/is}N₀

	ypT _{0/is} N ₀	No ypT _{0/is} N ₀		p	OR (95% CI)	p
Chemotherapy EC-D EC-P	11(2.41%) 67(14.73%)	98(21.54%) 279(61.32%)	5.017	0.025	1.797(0.882, 3.660)	0.106
Age of diagnosis ≤45 45–60 >60	23(5.05%) 41(9.01%) 14(3.08%)	126(27.69%) 195(42.86%) 56(12.31%)	0.717	0.699		
Menstrual status Premenopausal Peri-menopause Postmenopausal Unknown	42(9.23%) 1(0.22%) 35(7.69%) 0(0)	197(43.30%) 11(2.42%) 162(35.60%) 7(1.54%)	2.189	0.534		
Molecular type Luminal A Luminal B Her2 overexpression TNBC Unknown	0(0) 26(5.71%) 31(6.81%) 21(4.62%) 0(0)	14(3.08%) 222(48.79%) 69(15.16%) 62(13.63%) 10(2.20%)	30.116	<0.001	9.495(2.492, 36.176)	0.001
ER status Positive Negative Unknown	26(5.71%) 52(11.43%) 0(0)	235(51.65%) 133(29.23%) 9(1.98%)	26.998	<0.001	0.085(0.013, 0.561)	0.01
PR status Positive Negative Unknown	15(3.30%) 63(13.84%) 0(0)	185(40.66%) 181(39.78%) 11(2.42%)	28.301	<0.001	1.395(0.46, 4.23)	0.556
Her-2 status Positive Negative Unknown	48(10.55%) 30(6.59%) 0(0)	130(28.57%) 236(51.87%) 11(2.42%)	20.81	<0.001	0.055(0.017, 0.183)	<0.001
Ki-67 index ≤ 14% > 14% Unknown	1(0.22%) 77(16.92%) 0(0)	31(6.81%) 336(73.85%) 10(2.20%)	7.151	0.028	0.444(0.089, 2.219)	0.323

The univariable analysis for pCR of ypT₀N₀ in NAC found that the significant prognostic factors were chemotherapy scheme, molecular type, ER status, and PR status ($P<0.05$; Table 3). In the multivariable regression analysis, chemotherapy scheme (OR: 3.379, 95% CI: 1.373–8.314), molecular type (OR: 21.3, 95% CI: 3.651–124.264) and ER status (OR: 0.104, 95% CI: 0.011–0.991) ($P<0.05$) were identified as the significant independent predictors.

Tables 4 and 5 show the two types of pCR in the chemotherapy of EC-D. Clearly, ER status and Her-2

status were prognostic factors of ypT_{0/is}N₀, while ER status and Her-2 status were not the independent predictors of ypT_{0/is}N₀ (both $P>0.05$). However, none of the factors mentioned above can affect ypT₀N₀ in the chemotherapy of EC-D. Similarly, the univariable analysis showed the prognostic factors for ypT_{0/is}N₀ in the chemotherapy of EC-P were molecular type, ER status, PR status, Her-2 status, and Ki-67 index ($P<0.05$; Table 6). Then, the multivariable regression analysis uncovered molecular type (OR: 4.214, 95% CI: 1.105–16.065) and Her-2 status

Table 3 The Analysis of ypT₀N₀

	ypT ₀ N ₀	No ypT ₀ N ₀		p	OR (95% CI)	p
Chemotherapy EC-D EC-P	6(1.32%) 43(9.45%)	103(22.64%) 303(66.59%)	4.134	0.042	3.379(1.373, 8.314)	0.008
Age of diagnosis ≤45 45–60 >60	13(2.85%) 24(5.28%) 12(2.64%)	136(29.89%) 212(46.59%) 58(12.75%)	3.696	0.158		
Menstrual status Premenopausal Peri-menopause Postmenopausal Unknown	20(4.40%) 1(0.22%) 28(6.15%) 0(0)	219(48.13%) 11(2.42%) 169(37.14%) 7(1.54%)	4.784	0.188		
Molecular type Luminal A Luminal B Her2 overexpression TNBC Unknown	0(0) 11(2.42%) 20(4.39%) 18(3.95%) 0(0)	14(3.08%) 237(52.09%) 80(17.58%) 65(14.29%) 10(2.20%)	32.412	<0.001	21.3(3.651, 124.264)	0.001
ER status Positive Negative Unknown	11(2.42%) 38(8.35%) 0(0)	250(54.94%) 147(32.31%) 9(1.98%)	31.137	<0.001	0.104(0.011, 0.991)	0.049
PR status Positive Negative Unknown	6(1.32%) 43(9.45%) 0(0)	194(42.64%) 201(44.17%) 11(2.42%)	25.818	<0.001	0.262(0.059, 1.154)	0.077
Her-2 status Positive Negative Unknown	26(5.71%) 23(5.05%) 0(0)	152(33.41%) 243(53.41%) 11(2.42%)	5.303	0.071		
Ki-67 index ≤ 14% > 14% Unknown	0(0) 49(10.77%) 0(0)	32(7.03%) 364(80.00%) 10(2.20%)	5.584	0.061		

(OR: 0.126, 95% CI: 0.038–0.414) were the independent predictors.

Finally, prognostic factors of ypT₀N₀ in the EC-P chemotherapy were molecular type, ER status, and PR status ($P < 0.05$; Table 7). Nevertheless, molecular type (OR: 11.571, 95% CI: 1.838–72.83) was found as the independent predictor.

Some OR and 95% CI in the table are blank, which is meaningless because the chi-square test proved that these factors do not have independent influences, so this article did not fill it into the tables.

Side Effects

Due to the limitations of data collection, we only collected blood data from 317 patients, who received either EC-D (n=87) or EC-P (n=230). No significant difference was found in platelet count in patients treated with EC-D (27.4%) or EC-P (72.6%) ($P = 0.7683$) (Table 8). No significant difference was identified in proportions of urea in patients treated with EC-D (27.4%) or EC-P (72.6%) ($P = 0.399$). The hemoglobin levels were significantly different between EC-D and EC-P ($P = 0.0021$). EC-P had

Table 4 The ypT_{0/is}N₀ Rate Analysis of EC-D

EC-D	ypT _{0/is} N ₀	No ypT _{0/is} N ₀		p	OR (95% CI)	p'
Age of diagnosis			1.883	0.39		
≤45	1	27				
45–60	7	53				
>60	3	18				
Menstrual status			1.465	0.69		
Premenopausal	4	47				
Peri-menopause	1	3				
Postmenopausal	6	47				
Unknown	0	1				
Molecular type			8.272	0.082		
Luminal A	0	1				
Luminal B	3	66				
Her2 overexpression	6	22				
TNBC	2	7				
Unknown	0	2				
ER status			8.756	0.013	—	1
Positive	3	68				
Negative	8	28				
Unknown	0	2				
PR status			3.834	0.147		
Positive	2	45				
Negative	9	50				
Unknown	0	3				
Her-2 status			7.494	0.024		0.997
Positive	9	38				
Negative	2	58				
Unknown	0	2				
Ki-67 index			0.588	0.745		
≤ 14%	0	3				
> 14%	11	93				
Unknown	0	2				

a greater impact on the decline of hemoglobin level than EC-D. Furthermore, the creatinine levels were significantly different between treatment with EC-D and EC-P ($P=0.0004$). Also, EC-P had a greater impact on the decline of creatinine level than EC-D.

Trastuzumab Treatment

A total of 178 patients showed Her-2 (+) (Table 9), and 126 received trastuzumab, in them 40 (31.75%) patients got ypT_{0/is}N₀, and 23 (18.25%) patients obtained ypT₀N₀. The remaining 52 patients did not use trastuzumab, only 9 (17.31%) got ypT_{0/is}N₀, and 4 (7.69%) obtained ypT₀N₀. The pCR rate of patients who used trastuzumab was significantly higher than that of

patients who were not used, whether it was ypT_{0/is}N₀ nor ypT₀N₀ ($p<0.05$).

Discussion

Breast cancer is a heterogeneous malignant tumor. Although the clinical and pathological types are similar, the prognosis and survival rate of cancer may be completely different.⁵

Therefore, the accurate chemotherapy is significant, especially in NAC. IHC has been used to distinguish the molecular type of breast cancer and assess the link between pathological response^{6–8} and long-term survival.^{9,10} As reported, response to preoperative chemotherapy can predict the prognosis of breast cancer^{11–13}

Table 5 The ypT₀N₀ Rate Analysis of EC-D

EC-D	ypT ₀ N ₀	No ypT ₀ N ₀		p	OR (95% CI)	p'
Age of diagnosis			0.379	0.827		
≤45	1	27				
45–60	4	56				
>60	1	20				
Menstrual status			3.229	0.358		
Premenopausal	2	49				
Peri-menopause	1	3				
Postmenopausal	3	50				
Unknown	0	1				
Molecular type			3.081	0.544		
Luminal A	0	1				
Luminal B	2	67				
Her2 overexpression	3	25				
TNBC	1	8				
Unknown	0	2				
ER status			3.278	0.194		
Positive	2	69				
Negative	4	32				
Unknown	0	2				
PR status			0.5	0.779		
Positive	2	45				
Negative	4	55				
Unknown	0	3				
Her-2 status			4.197	0.123		
Positive	5	42				
Negative	1	59				
Unknown	0	2				
Ki-67 index			0.305	0.858		
≤ 14%	0	3				
> 14%	6	98				
Unknown	0	2				

which makes pCR become an evaluation method for the efficacy of preoperative chemotherapy.

The two pCRs of NAC were associated with chemotherapy scheme, molecular type, ER status, and PR status. Differently, ypT₀/isN₀ was also linked with Her-2 status and ki-67 index. Further analysis suggested that patients receiving EC-P with ER negativity and Her-2 gene amplification more easily reach the pCR of ypT₀/isN₀. And these patients with negative ER would more easily reach the pCR of ypT₀N₀. Our conclusions were also consistent with previous research. In a study involving 1731 patients treated with different neoadjuvant regimens, the pCR rates in the patients with ER (-) tumors versus ER (+) tumors were

significantly higher (24% vs 8%), no matter what treatment was taken.¹⁴ In addition, patients with basal-like and HER2 (+) diseases reached the higher rate of pCR, whereas the luminal tumors had a lower pCR rate.⁶ Furthermore, the Ki-67 index was extraordinarily lower after treatment, suggesting chemotherapy has an effective anti-proliferative effect on tumors.¹⁵

In the arm of EC-D, 11 of 109 (10.0%) patients were ypT₀/isN₀, which was similar to another study that 4 of 41 (9.8%) patients had a pCR to chemotherapy.¹⁶ Moreover, 6 of 109 (5.5%) patients were ypT₀N₀. These results implied that the pCR of ypT₀/isN₀ can be more easily reached. This is a good explanation that DCIS is insensitive to

Table 6 The ypT_{0/is}N₀ Rate Analysis of EC-P

EC-P	ypT _{0/is} N ₀	No ypT _{0/is} N ₀		p	OR (95% CI)	p'
Age of diagnosis			0.407	0.816		
≤45	22	99				
45–60	34	142				
>60	11	38				
Menstrual status			3.504	0.32		
Premenopausal	38	150				
Peri-menopause	0	8				
Postmenopausal	29	115				
Unknown	0	6				
Molecular type			22.673	<0.001	4.214(1.105, 16.065)	0.035
Luminal A	0	13				
Luminal B	23	156				
Her2 overexpression	25	47				
TNBC	19	55				
Unknown	0	8				
ER status			17.955	<0.001	0.253(0.036, 1.796)	0.17
Positive	23	167				
Negative	44	105				
Unknown	0	7				
PR status			24.93	<0.001	2.439(0.619, 9.608)	0.203
Positive	13	140				
Negative	54	131				
Unknown	0	8				
Her-2 status			15.643	<0.001	0.126(0.038, 0.414)	0.001
Positive	39	92				
Negative	28	178				
Unknown	0	9				
Ki-67 index			7.414	0.025	0.397(0.088, 1.789)	0.229
≤ 14%	1	28				
> 14%	66	243				
Unknown	0	8				

chemotherapy. But we did not find the difference of EC-D with the pCR of ypT_{0/is}N₀ or ypT₀N₀.

In the arm of EC-P, 67 (19.4%) and 43 (12.4%) of 346 patients accepted ypT_{0/is}N₀ and ypT₀N₀ respectively. In terms of molecular type, no luminal A patients achieved pCR. Moreover, 23 (12.9%) and 9 (5.0%) of 178 luminal B patients accepted ypT_{0/is}N₀ and ypT₀N₀ respectively. Also, 25 (34.7%) and 17 (23.6%) of 72 patients with Her-2 overexpression were ypT_{0/is}N₀ and ypT₀N₀ respectively. About 19 (25.7%) and 17 (23.0%) of 74 triple-negative patients were ypT_{0/is}N₀ and ypT₀N₀ respectively. About 20.8% of breast cancer patients exhibited HER-2 overexpression, which was similar to other studies (15–25%)^{17–19}. In terms of ER (+) tumors, the rate of

pCR in anthracycline and taxane combined NAC was between 6% and 12%,²⁰ which was slightly higher than our rate. Probably we prioritized surgery for luminal tumors because of the low rate of pCR, and the patients included in this study had locally more advanced tumor, so these patients relatively achieved pCR difficultly.

The two pCRs of EC-P were both linked with molecular type, ER status, and PR status. The ypT_{0/is}N₀ of EC-P was also associated with both Her-2 status and Ki-67 index. The patients with Her-2 gene amplification achieved pCR more easily. This finding was the same as that of EC-D.

The rate of pCR of EC-P was higher than that of EC-D. Moreover, EC-P shortened the medication time, and

Table 7 The ypT₀N₀ Rate Analysis of EC-P

EC-P	ypT ₀ N ₀	No ypT ₀ N ₀		p	OR (95% CI)	p'
Age of diagnosis			5.405	0.067		
≤45	12	109				
45–60	20	156				
>60	11	38				
Menstrual status			6.613	0.085		
Premenopausal	18	170				
Peri-menopause	0	8				
Postmenopausal	25	119				
Unknown	0	6				
Molecular type			27.821	<0.001	11.571(1.838, 72.83)	0.009
Luminal A	0	13				
Luminal B	9	170				
Her2 overexpression	17	55				
TNBC	17	57				
Unknown	0	8				
ER status			26.102	<0.001	0.22(0.021, 2.329)	0.208
Positive	9	181				
Negative	34	115				
Unknown	0	7				
PR status			27.402	<0.001	0.463(0.088, 2.429)	0.362
Positive	4	149				
Negative	39	146				
Unknown	0	8				
Her-2 status			3.418	0.181		
Positive	21	110				
Negative	22	184				
Unknown	0	9				
Ki-67 index			5.88	0.053		
≤ 14%	0	29				
> 14%	43	266				
Unknown	0	8				

Table 8 Blood and Kidney Marker Analysis

	EC-D (n=87)	EC-P (n=230)	z	P
HGB	-0.06(-0.12, -0.01)	-0.1 (-0.15, -0.05)	3.07	0.0021
PLA	-0.01(-0.17,0.11)	-0.03(-0.17,0.13)	0.295	0.7683
UREA	0.04(-0.18,0.27)	0.00(-0.22,0.25)	0.843	0.399
Cr	0.00 (-0.07,0.07)	-0.06(-0.14,0.03)	3.527	0.0004

Table 9 Trastuzumab Analysis

	Total	ypT ₀ /isN ₀	ypT ₀ N ₀
Trastuzumab	126	40(31.70%)	23(18.25%)
No trastuzumab	52	9(17.31%)	4(7.69%)
p		<0.05	<0.05

increased dose density, and then made patients to accept surgery in time. Some small-sized uncontrolled studies demonstrated breast cancer women with poor-prognosis can benefit from high-dose chemotherapy, which prolonged disease-free survival and overall survival.^{21,22} The increased dose intensity and total dose of adjuvant

chemotherapy can improve the outcomes of breast cancer patients.²³ In addition, the higher dose intensity with the adjunction of filgrastim can significantly improve the survival of node-positive patients.²² Although there is no clear clinical trial in NAC for shortening the chemotherapy interval and increasing the dose of chemotherapy, theoretical basis previously obtained in adjuvant chemotherapy

implies these studies benefit some patients with NAC and call for new clinical studies.

We showed differences in two definitions of pCR whether DCIS was left in breasts or not. Therefore, it is necessary to reach a consensus on the definition of PCR in NAC, especially if PCR is determined as an alternative end-point of prognosis.²⁴ No obvious difference in platelet or urea was found between EC-D and EC-P, implying that patients with similar platelet or urea can choose and benefit from NAC of EC-P. However, a significant difference was identified in creatinine level and hemoglobin level, indicating EC-P can more significantly reduce the creatinine level than EC-D. Thus, patients with anemia or renal insufficiency should choose NAC more cautiously. The hemoglobin levels of patients after chemotherapy were lower than those of the healthy group. During chemotherapy, the patients will experience a decrease in hemoglobin level, but the hemoglobin level will reverse after the treatment.²⁵ Reportedly, the tumor characteristics such as tumor stage or hormone-receptor status had no significant influence on the occurrence of anemia.²⁶ Thus, the decline of hemoglobin level was only linked to chemotherapy. Most hematological parameters remained constant throughout the treatment period, but creatinine and hemoglobin levels were slightly regulated at different stages.²⁷ In summary, EC-P has a shorter interval between chemotherapy, so it more considerably impacts hemoglobin and creatinine levels.

In the patients with Her-2 (+), the PCR rate of patients who used trastuzumab was significantly higher than that of patients who were not used, whether it was ypT_{0/is}N₀ nor ypT₀N₀. The NOAH trial²⁸ divided the enrolled HER-2 positive breast cancer patients into a chemotherapy alone group and a chemotherapy combined trastuzumab group. The results showed that the pathological complete remission of the trastuzumab group was achieved. pCR rate is higher than that of the chemotherapy alone group, and in patients receiving trastuzumab, Event-free survival (EFS) is closely related to pCR. These results indicated that neoadjuvant therapy with trastuzumab can improve the prognosis of patients with Her-2 (+) locally advanced or inflammatory breast cancer. This proves the unshakable status of trastuzumab in the neoadjuvant treatment of Her-2 (+) breast cancer.

This study has some limitations. Firstly, systematic G-CSF was applied to every patient, so we cannot clearly understand the myelosuppressive effects of chemotherapy and thus cannot choose chemotherapy according to myelosuppression. Secondly, we did not investigate survival.

Nevertheless, this is the first study to examine the efficacy of EC-D and EC-P as NAC regimens.

In conclusion, the efficacy of EC-P is better than EC-D in NAC, especially in patients with ER (-), PR (-), Her-2 (+) and high Ki-67 expression. Patients with Her-2 overexpression and triple negativity can more easily accept pCR in EC-P, regardless of the definition of pCR. Consensus on the definition of pCR in NAC is urgently needed, especially if pCR is to be determined as a surrogate end-point for Prognosis. In terms of toxicity, patients with a similar platelet or urea can benefit from EC-P, and patients with anemia or renal insufficiency should choose EC-P more cautiously.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81572602).

Disclosure

The authors declare no conflicts of interests in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(1):7–30. doi:10.3322/caac.21442
2. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. *Cochrane Database Syst Rev*. 2007;CD005002.
3. Peto R, Davies C, Godwin J, et al. Comparisons between different poly-chemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. *Lancet*. 2012;379(9814):432–444. doi:10.1016/S0140-6736(11)61625-5
4. Vriens BE, Aarts MJ, de Vries B, et al., Breast Cancer Trialists' Group of the Netherlands (BOOG). Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. *Eur J Cancer*. 2013;49(15):3102–3110. doi:10.1016/j.ejca.2013.06.012
5. Wu J, Li S, Jia W, Su F. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. *J Cancer Res Clin Oncol*. 2011;137(10):1505–1510. doi:10.1007/s00432-011-1029-6
6. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res*. 2005;11(16):5678–5685. doi:10.1158/1078-0432.CCR-04-2421
7. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res*. 2007;13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109
8. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*. 2008;26(8):1275–1281. doi:10.1200/JCO.2007.14.4147
9. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer*. 2007;109(9):1721–1728. doi:10.1002/cncr.22618

10. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. *Cancer Res.* 2008;68(9):3108–3114. doi:10.1158/0008-5472.CAN-07-5644
11. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. *J Natl Cancer Inst Monogr.* 2001;2001(30):96–102. doi:10.1093/oxfordjournals.jnci-monographs.a003469
12. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. *J Clin Oncol.* 2003;21(22):4165–4174. doi:10.1200/JCO.2003.12.005
13. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. *J Clin Oncol.* 2008;26(5):778–785. doi:10.1200/JCO.2007.15.0235
14. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. *J Clin Oncol.* 2006;24(7):1037–1044. doi:10.1200/JCO.2005.02.6914
15. Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. *Br J Cancer.* 2005;92(1):147–155. doi:10.1038/sj.bjc.6602256
16. Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. *J Clin Oncol.* 2012;30(15):1747–1749. doi:10.1200/JCO.2011.41.3161
17. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science.* 1987;235(4785):177–182. doi:10.1126/science.3798106
18. Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science.* 1989;244(4905):707–712. doi:10.1126/science.2470152
19. Kathleen MD, Pritchard I, Shepherd LE, O'Malley FP, Andrulis IL. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. *N Engl J Med.* 2006;354(20):2103–2111. doi:10.1056/NEJMoa054504
20. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. *J Clin Oncol.* 2005;23(29):7265–7277. doi:10.1200/JCO.2005.02.0818
21. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. *Ann Oncol.* 2002;13(5):689–698. doi:10.1093/annonc/mdf203
22. Citron ML, Berry DA, Cirincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. *J Clin Oncol.* 2003;21(8):1431–1439. doi:10.1200/JCO.2003.09.081
23. BONADONNA MDGIANNI, PINUCCIA VALAGUSSA BS, Moliterni Mdangela. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. *N Engl J Med.* 1995;332(14):901–906. doi:10.1056/NEJM199504063321401
24. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol.* 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.8595
25. Loo WT, Yip MC, Chow LW, et al. A pilot study: application of hemoglobin and cortisol levels, and a memory test to evaluate the quality of life of breast cancer patients on chemotherapy. *Int J Biol Markers.* 2013;28(4):e348–356. doi:10.5301/IBM.5000053
26. Denison U, Baumann J, Peters-Engl C, Samonigg H. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. *Breast Cancer Res Treat.* 2003;79(3):347–353. doi:10.1023/A:1024016508925
27. Paz M, Gomes ALJ, Islam MT, et al. Assessment of chemotherapy on various biochemical markers in breast cancer patients. *J Cell Biochem.* 2018;119(3):2923–2928. doi:10.1002/jcb.26487
28. Luca Gianni WE, Semiglazov V, Lluch A, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet Oncol.* 2014;15.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

Dovepress

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.